Biological Products, (No Diagnostic Substances)
Surrozen, Inc./DE (SRZN) stock: what's happening now, every material event decoded in plain English, P/E and valuation, analyst ratings, and insider buying and selling.
AllSight quality score: 49/100 — a percentile rank of Surrozen, Inc./DE’s fundamentals against Manufacturing peers.
Is Surrozen, Inc./DE overvalued? P/S looks fair vs its 5-year range.
Consensus: Buy from 6 analysts (Buy 4 · Sell 2).
Average price target: $67.00 (+118.5% vs $30.67); range $54–$80.
Wall Street analyst consensus, shown as context — not an AllSight view.
Open-market buys: 84 · Open-market sells: 13 · Net: −$14.8M
Coordinated block · likely financing, not open-market conviction.
Discretionary open-market purchases are the signal; grants, option exercises and Rule 10b5-1 scheduled trades are context, not counted in the balance. Facts only — not a recommendation. Source: SEC Form 4 filings on EDGAR.
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!